In order to strengthen its gene editing capabilities, Vertex Pharmaceuticals has entered into a multi-target license and option agreement with Orum Therapeutics for the discovery of novel targeted conditioning agents for use with gene editing. The agreement, that could be worth up to US$945 M, will leverage Orum’s Dual-Precision Targeted Protein Degradation (TPD²®) technology platform along with Vertex’s gene editing expertise to develop novel degrader-antibody conjugates (DACs) as targeted conditioning agents for use with gene editing therapies